Olimestra (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olimestra, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat high blood pressure in adults. GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olimestra is an angiotensin II receptor blocker indicated for conditions affecting the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: improves symptoms and may reduce hospitalisation when used with standard therapy. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.

Adverse reactions to olmesartan are reported across a spectrum of frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevation - Bullous pemphigoid skin disorder

Olimestra should be used with attention to patient‑specific factors and monitoring requirements.

- Renal impairment: adjust dose or avoid if severe. - Hepatic impairment: use with caution; monitor liver function. - Electrolyte disturbances: monitor potassium levels. - Concomitant diuretics: watch for additive blood‑pressure lowering effects. - Pregnancy: contraindicated in the second and third trimesters. Store at ambient temperature: keep the tablets in the original pack so the by ​​​  ​   ​    

Store ​​​​  ​ ​  ...

Olimestra has  

Major